Artificial intelligence

Naheed-Kurji,-president-and-CEO,-Cyclica-3-20

Newco news

Nineteengale is born, a spinout of Neurotheryx and Cyclica

March 20, 2020

Nineteengale Therapeutics is a new joint venture that was launched to fill a large void. Cyclica Inc., along with its partner, Neurotheryx Canada Ltd., both of Toronto, created Nineteengale to find and develop cannabinoid-inspired drugs for bipolar disorder, anxiety and pain management.

Biopharma companies turning to artificial intelligence for drug discovery

March 17, 2020

By Peter Winter

No Comments

The importance of artificial intelligence and machine learning (AI/ML) has not been lost on drug development companies. Recently, to help accelerate the discovery of therapies to treat COVID-19, several deals have been established to help deploy those tools.

Bridge Biotherapeutics taps Atomwise in potential $1B AI-based discovery deal

March 10, 2020

By Michael Fitzhugh

No Comments

South Korea's Bridge Biotherapeutics Inc. has enlisted San Francisco-based AI drug discovery shop Atomwise Inc. to help it identify up to 13 small-molecule inhibitors of Pellino proteins and other targets in an effort to develop new therapies for inflammatory diseases. Atomwise stands to receive an up-front payment of undisclosed value, as well as milestone and royalty payments under terms of the deal. Presuming success, it estimates the partnership's payoff could reach up to $1.08 billion.

AI partnerships ‘move the industry forward’

Trial recruitment, retention improved but drop-outs persist in late studies

February 11, 2020

By Marie Powers

No Comments

Multiple tactics employed by the biopharma industry to improve the recruitment and retention of participants in clinical trials seem to be paying off. More than three of four (77%) studies now fully enroll on or ahead of schedule, according to researchers at the Tufts Center for the Study of Drug Development (CSDD), reporting in the January/February Tufts CSDD Impact Report on global recruitment performance benchmarks.

Newco news

AI startup Zebiai inks new deals with Google and X-Chem

January 14, 2020

By Lee Landenberger

No Comments

When Zebiai Therapeutics Inc.’s CEO, Rick Wagner, went about naming his new machine learning company, he wanted it to connote something dramatic that displayed the company’s potential to reach into the seemingly boundless future technology had unlocked.

Data rich environment

Artificial intelligence: pushing the boundaries of drug development

December 30, 2019

By Peter Winter

No Comments

The next wave of drug discovery is being enabled by artificial intelligence (AI). This fact has not been lost on investors, who are keeping a close watch on emerging biopharma companies that are using AI and machine learning to enable the discovery of next-generation medicines.

Year in Review: From capital markets to CRISPR, 2019 a pretty good year for biopharma

December 30, 2019

No Comments

For biopharma, 2019 can be described as a terrific year – with a few asterisks. The financial markets were flourishing, with venture capital dollars, in particular, flowing to the sector, while dealmaking reached historic proportions. Meanwhile, scientific breakthroughs led the way as cell and gene therapies gained ground, the first signs of success emerged with new technologies like CRISPR and the long-awaited promise of genomics found its way to the front lines of health care.

'The new gold rush'

AI, machine learning offer hope for speeding Alzheimer’s development

December 16, 2019

By Brian Orelli

No Comments

Machine learning and artificial intelligence (AI) are already being actively used in drug discovery to evaluate potential binding of small-molecule drugs to proteins, but there's potential for the technologies to be used on the development side as well, especially in hard-to-treat diseases such as Alzheimer's disease.

Evaxion AI platforms speed time to personalized immunotherapies, vaccines

September 11, 2019

By Annette Boyle

No Comments

Evaxion Biotech A/S is leveraging two artificial intelligence (AI) platforms to quickly identify targets for cancer immunotherapies and infectious diseases.

Ethical issues trailing AI are writ large in health care

August 30, 2019

By Nuala Moran

No Comments

LONDON – The future role of artificial intelligence (AI) in health in the U.K. was cemented recently with the announcement of £250 million (US$301 million) in government funding to set up a dedicated AI laboratory that will work to systematically apply the technology and harness the benefits at a national level.

Artificial intelligence, BioWorld
RSS

Nineteengale is born, a spinout of Neurotheryx and Cyclica

Biopharma companies turning to artificial intelligence for drug discovery

Bridge Biotherapeutics taps Atomwise in potential $1B AI-based discovery deal

Trial recruitment, retention improved but drop-outs persist in late studies

AI startup Zebiai inks new deals with Google and X-Chem

Artificial intelligence: pushing the boundaries of drug development

Year in Review: From capital markets to CRISPR, 2019 a pretty good year for biopharma

AI, machine learning offer hope for speeding Alzheimer’s development

Evaxion AI platforms speed time to personalized immunotherapies, vaccines

Ethical issues trailing AI are writ large in health care

Popular Stories

South Korea approves first four COVID-19 test kits under urgent-use license

Two South Korean COVID-19 kits look overseas, seek FDA approval

Noninvasive ventilation options explored for COVID-19, as FDA eases with guidance

FDA says yes to NO: Bellerophon Therapeutics wins expanded access approval for inhaled nitric oxide system

Antiviral favipiravir effective against COVID-19, China says

BioWorld Premium

Artificial intelligence, BioWorld RSS

Popular Stories

BioWorld Premium

Artificial intelligence, BioWorld
RSS